Kala Pharmaceuticals/$KALA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Kala Pharmaceuticals
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
- Ticker
- $KALA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 6
- Headquarters
- Arlington, United States
- Website
- www.kalarx.com
KALA Metrics
BasicAdvanced
$3.3M
-
-$1.30
-2.29
-
Price and volume
Market cap
$3.3M
Beta
-2.29
52-week high
$3.96
52-week low
$0.11
Average daily volume
421K
Financial strength
Current ratio
6.88
Quick ratio
4.839
Interest coverage (TTM)
-22.11%
Profitability
EBITDA (TTM)
-24.069
Management effectiveness
Return on assets (TTM)
-65.43%
Return on equity (TTM)
-345.32%
Valuation
Price to book
0.37
Price to tangible book (TTM)
0.37
Price to free cash flow (TTM)
-0.067
Free cash flow yield (TTM)
-1,501.50%
Free cash flow per share (TTM)
-2.567
Growth
Earnings per share change (TTM)
-99.61%
3-year earnings per share growth (CAGR)
-82.13%
KALA Financial Performance
Revenues and expenses
KALA Earnings Performance
Company profitability
Upcoming events
No upcoming events
KALA News
AllArticlesVideos
KALA BIO Announces Reverse Stock Split
Newsfile Corp6 hours ago
KALA BIO Provides CEO Update and Preliminary Third Quarter 2026 Financial Results
Newsfile Corp3 days ago
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Newsfile Corp1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.